Pharma’s engineers are creating new, modular flexible and scalable process and manufacturing environments to meet cost, quality and patient-first challenges head on
Pharmaceutical manufacturers remain under constant pressure to accelerate innovation and the speed at which it can introduce successful therapeutics and better health outcomes to patients around the world. An array of megatrends and scientific advances are fueling a fresh wave of innovation, supported by a more pragmatic approach to regulating by the FDA, with recent reforms intended to accelerate the industry’s throughput of life-saving, disease killing medicines and therapeutics.
With Tufts and other institutions estimating the cost of developing a successful first-in-class therapy more than $2 billion, optimizing every aspect of development and manufacturing has become mandatory; not only for better bottom-line company financials and payer affordability goals, but to promote the best outcomes for patients.